LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, announced today that management has commenced the preliminary due diligence and strategic planning process for the Company’s planned expansion into Colombia. The initial phase includes evaluating corporate, regulatory, legal, operational, and commercial requirements for establishing a Colombian operating subsidiary and supporting the future deployment of the Company’s digital healthcare platform.
Management believes Colombia represents an attractive long-term market as the Company continues advancing its broader Latin American expansion strategy. The ongoing review process is expected to include assessments of corporate formation, regulatory compliance, healthcare technology implementation, strategic partnerships, local operational infrastructure, and other market entry considerations necessary to support future operations.
The Company further noted that the evaluation is intended to build upon its growing healthcare ecosystem by identifying opportunities to expand access to telehealth infrastructure, healthcare coordination technologies, digital healthcare services, insurance accessibility initiatives, pharmacy integration opportunities, payment accessibility solutions, and artificial intelligence-driven healthcare technologies in additional Latin American markets.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: “Colombia represents an important strategic opportunity as we continue executing our long-term vision of building an integrated digital healthcare ecosystem across Latin America. While we remain in the early stages of evaluating market entry requirements, we believe it is important to establish the proper legal, operational, and strategic foundation before expanding into new jurisdictions. We are encouraged by the opportunities we see in Colombia and look forward to providing updates as the evaluation process progresses.”
The Company emphasized that the Colombia expansion initiative remains in the preliminary planning and due diligence stage. Management intends to complete the required corporate, regulatory, and operational review before proceeding with the establishment of a Colombian subsidiary and expects to provide additional updates as material developments occur.
For additional information, visit https://latamed.ai or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
